Coverage / BMY / Trade Card

BMY

Bristol-Myers Squibb Co

OPPORTUNISTIC BUY 2026-08-01 Updated today USD 65.31 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
62

Position levels

Currenttoday
USD 65.31
Buy <=wait / entry
USD 54.33
Trim >=take some off
USD 67.00
Thesis breakA material adverse outcome on the Arcus or Hengrui licensing programmes (such as...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case29%100 / 10029.0
Base case50%62 / 10031.0
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Q2 2026 earnings beat with EPS of $2.04 vs $1.60 consensus and revenue of $12.97B vs $11.74B estimates
  • Strategic collaboration with Arcus Biosciences for oncology treatment regimen
  • Strategic agreements with Hengrui Pharma to advance medicines in oncology, hematology, and immunology
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.